Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prehypertension was defined as a discrete category in 1993. There is evidence to support active management of this entity given the increased risk of hypertension, cardiovascular disease, heart failure, and stroke. There have been few comprehensive summaries on the management of this population. Therefore, this article summarizes the latest guidelines and studies on the detection, evaluation, and management of prehypertension.
 ...
PMID:Prehypertension: detection, evaluation, and management. 1864 83

Prehypertension (pHTN) and metabolic syndrome (MetS) are both lifestyle diseases that are potentiated by increased adiposity, as both disease processes are closely related to weight. In the case of pHTN, increased adiposity causes dysregulation of the renin-angiotensin-aldosterone-system (RAAS) as well as adipokine- and leptin-associated increases in adrenergic tone. In MetS, excess weight potentiates hyperglycemia and insulin resistance which causes positive feedback into the RAAS system, activates an inflammatory cascade that potentiates atherosclerosis, and causes lipid dysregulation which together contribute to cardiovascular disease, especially coronary heart disease (CHD) and heart failure (HF). The relationship with all-cause mortality is not as clear-cut in part because of some protective effects associated with the obesity paradox in chronic diseases such as CHD and HF. However, in healthy populations, the absence of excess weight and its associated effects on prehypertension and MetS are associated with a longer absolute and disease-free lifespan.
 ...
PMID:Cardiovascular Risk in Patients with Prehypertension and the Metabolic Syndrome. 2951 7